

CORPORATE PROFILE

HEALTHY, FIT & STRONG

SEPTEMBER 2007

DISCLAIMER

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS TO PURCHASE, ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as" anticipate", "target", "expect", "estimate", "intend", "expected", "plan", "goal" believe", or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States.


This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.




36.6 AT A GLANCE


We strive to be
Russia's leading
health & beauty
retailer and to
become the
preferred source of
medicines and
health & beauty
products for Russian
consumers

USD millions









GROWTH DRIVERS

GDP per Capita 2006 \$7,200

☐ Growing disposable income pushes consumption up

Disposable Income CAGR 14-16%

■ Booming H&B and Pharma industry followed by changes in consumer's behaviour

Pharma market 2007E \$14.0bln

☐ Improving economy in the regions provide for better opportunities of consolidation

Pharma market CAGR 12-15%


☐ Scale effect together with internal improvements in operations management ensure higher future profitability

Source: Investment banks researches, Pharmexpert, DSM

CAGR for `07-`11

STORES GROWTH

FY06 Sales breakdown



REGIONAL EXPANSION

Business-Units

MOSCOW 374
URALS 336
VOLGA 131
SOUTH 132
WEST. SIBERIA 42
NORTH-WEST 32

the Company reaches out to every Russian city with a population of over 500K people to enjoy 10-20% of the region's pharmacy retail market N. Novgorod 30% local Market share

Moscow 15% local Market share


Perm 40% local Market share

Ufa 30% local Market share

Rostov-on-Don 30% local Market share

Orenburg
25%
local Market share


currently operating **1052** pharmacies in 28 regions




As percentage of sales of commercial chains

SALES BREAK-DOWN

RETAIL




GROSS MARGIN RETAIL



COMPETITION

Regional
penetration will be
achieved both
through organic
openings and
acquisitions of the
regional chains

This is subject to successful competition with a few other chains developing nationwide



Pharmexpert, Company estimations

BRAND & CUSTOMERS




36.6 membered

MALINA - new
loyalty program to
gather leading
companies of the
Russian consumer
sector


Source: Gallup Media Survey'06

A/R/M/I-Marketing data,
June, 2006

Brand awareness



Shopping experience



DIFFERENTIATION

New projects launched by

36.6 aimed to differentiate our product assortment and to obtain higher gross margins

Cosmetics centers

located in over 50 major pharmacies



Boots brands 600 SKU's of Boots products are sold countrywide



Exclusive offerings

Eclipse, Monteil, Champneys implants etc







Optics

7 stores and 22 opticians departments



DIFFERENTIATION

PRIVATE LABEL

We target the most successful product categories to launch private label products

Basic H&B



Parapharma & OTC



- 210 SKU`s available
- 2.5mln sales volume in 2006
- 67% average gross margin
- over 150 products in pipeline
- 10% share in retail sales by 2011

Natura & MedResponse



Convenience goods



DIVERSIFICATION

MEDICAL SERVICES



In July 2006 we acquired one of the best Moscow private clinics providing medical, surgical and dental services through EMC & EDC as well as full-scale laboratory

FY`06 SALES EBITDA

\$21mln 22%

Market

- fragmented with no potential core for consolidation
- non-satiated rapidly growing demand
- disturbed national healthcare system

Rationale/Strategy

 realize synergies between retail and medical services businesses by launching a chained operator in "masstige" market segment

DIVERSIFICATION

NEW PROJECTS

- franchise experience
- adjacent to pharmacy retail market segment
- exclusive child's play assortment for pharmacies
- own logistics and import operations

in USD mln.

NET SALES

GROSS MARGIN

PROFIT

ELC Stores

6 stores in Moscow



2007 plan

11.7

53 %

12 %



- Number of stores to be opened
 - 01.01.06
 01.07.07
 01.01.08 (plan)
 01.01.09 (plan)



- Investments in 1 store **\$160 K**
- Return of investments **3-4 years**

DIVERSIFICATION

NEW PROJECTS

- new format: discounter pharmacy and wide range of FMCG
- low level of opening expenses
- efficient operations in the larger stores in the regions
- 54% sales increase y-o-y
- 17% gross margin

MILA Stores

3 stores in Povoljie









LOGISTICS


In 2006 we started own supply chain system development

- invested \$10mln; additional \$10mln will be invested in 1-1,5 years
- higher margins secured
- exclusive assortment deliveries
- payback in 3 years



DISTRIBUTION SYSTEM

TURNOVER ARRANGEMENT




Supplier

Purchase agreement with ZAO «Apteki «36,6»

Regional wholesalers of holding.
The purchase agreement with ZAO «Apteki«36,6»

Regional crossdocking centers



BOARD OF DIRECTORS

Decision making is ensured by the balanced opinion of both shareholders and that of independent directors

Sergey KRIVOSHEEV Chairman, Co-founder

Artem BEKTEMIROV CEO, Co-founder

Michael OBERMAYER
Independent director,
Director Emeritus of
McKinsey & Company

Vassily RUDOMINO, Independent director, Partner in ALRUD law firm Vladimir STOLIN, Independent director, Chairman in ECOPSY consulting firm

MANAGEMENT STRUCTURE

Planning and operational controls are performed across the regional business units and product categories

Brand integrity and management as well as strategic business development and expansion are corporate major priorities

ARTEM BEKTEMIROV
CEO

ANTON PARKANSKY
Managing director

DMITRY GODUNOVOperations

KOZHAEVACommercial director

ALEXANDRA

CATEGORY DIRECTORS

SBORETS YULIA CFO

NATALIA MAKAROVA Human Resources

BORIS RYABOV
Business Technology
Development

KIRILL LEVASHOV
Medical director

REGIONAL BUSINESS UNITS **VICTOR VASILIEV**

Legal Council

OLEG ANIKINStrategy

MAXIM ARKHIPOV
Corporate Finance

& Investor Relations

ELENA KUKOLMarketing



FINANCIALS & ANALYSIS



Please note: reporting under IFRS since 2002 auditor Deloitte

1H2007 financials are non-audited

data by segments requires certain adjustments

INCOME STATEMENT CONSOLIDATED

	1H07	1H06	07/06	2006	2005	2004	2003	2002
REVENUE	390.5	218.6	79%	528.9	305.2	211.0	147.8	118.7
GROSS PROFIT	130.9	78.8	66%	183.4	117.8	80.2	59.8	46.0
EBITDA	15.0	9.2	64%	25.5	23.3	18.5	13.6	15.1
	3.8%	4.2%		4.8%	7.6%	8.8%	9.2%	12.7%
OPERATING INCOME	6.5	4.2	56%	12.5	13.8	11.5	8.4	10.4
SALE OF INV.	_	53.1		53.1	15.8	-	-	-
NET INCOME	-16.9	49.5	n/a	34.5	8.3	0.7	1.0	3.3
	-4.3%	22.6%		6.5%	2.7%	0.3%	0.7%	2.8%

in USD mln.

INCOME STATEMENT

CONSOLIDATED & SEGMENTED

	1H07	Retail	VERO	EMC	N-Core	Corp
REVENUE	390.5	302.9	59.5	12.7	15.4	
GROSS PROFIT	130.9	83.4	36.6	6.9	4.0	
	33.5%	27.5%	61.5%	54.7%	26.0%	
EBITDA	15.0	-3.0	17.0	3.5	-0.4	-2.1
	3.8%	-1.0%	28.6%	27.6%	-2.6%	n/a
OPERATING INCOME	6.5	-9.3	15.2	3.2	-0.4	-2.2
NET INCOME	-16.9	-12.5	11.0	2.3	-0.6	-17.1
	-4.3%	-4.1%	18.5%	18.2%	-3.9%	n/a

in USD mln.


BALANCE SHEET CONSOLIDATED

	H107	2006	2005	2004	2003	2002
N-CURRENT ASSETS	325.2	286.6	125.3	99.8	60.1	45.9
CURRENT ASSETS	295.3	238.7	119.4	72.5	53.0	38.8
TOTAL ASSETS	620.4	525.3	244.7	172.3	113.1	84.7
EQUITY	71.5	88.4	48.4	43.5	40.2	24.7
TOTAL DEBT	287.3	253.1	109.9	80.4	43.1	36.0
C-NT LIABILITIES*	142.9	131.8	64.5	40.0	24.9	20.1

^{*} Current Liabilities are non-interest bearing liabilities

BALANCE SHEET

CONSOLIDATED



CASH FLOW CONSOLIDATED & SEGMENTED

	2006	Retail	VERO	EMC	N-Core	Corp
profit before tax	51.6	-21.5	23.3	2.4	-1.3	48.7
profit before wcc	27.6	-1.3	30.8	2.7		-4.6
NET CASH in OA	-43.8	-32.4	-0.7	8.0	-5.7	-13.0
NET CASH in IA	-84.8	-137.9	-4.8	-0.2	-0.4	58.5
NET CASH from FA	128.3	13.1	3.4	-2.4		114.1
net cash	5.1	7.4	-0.1	0.5	0.8	-3.4


in USD mln.

INCOME STATEMENT RETAIL

	1H07	1H06	07/06	2006	2005	2004	2003	2002
REVENUE	302.9	157.8	92%	386.2	203.2	134.3	81.9	58.8
GROSS PROFIT	83.4	48.4	<i>72%</i>	112.2	67.2	45.4	26.3	19.2
	27.5%	30.7%		29.1%	33.1%	33.8%	32.1%	33%
EBITDA	-3.0	-0.1	n/a	-1.2	2.9	6.4	1.8	2.6
	-1.0%	-0.1%		-0.3%	1.4%	4.8%	2.2%	4.4%
OPERATING INCOME	-9.3	-4.6	n/a	-10.2	-2.5	2.6	-0.2	0.9

in USD mln.

KEY PERFORMANCE INDICATORS



BALANCE SHEET RETAIL

	1H07	2006	2005	2004	2003	2002
N-CURRENT ASSETS	258.3	226.3	85.4	59.5	21.9	15.7
CURRENT ASSETS	175.9	136.0	52.4	29.1	15.6	13.1
TOTAL ASSETS	434.2	362.3	137.8	88.6	37.4	28.8
LONG-TERM LIAB.	5.2	4.8	4.6	4.7	1.9	11.1
C-NT LIABILITIES	166.5	136.1	58.2	27.3	35.3	15.2



INCOME STATEMENT VEROPHARM

	1H07	1H06	07/06	2006	2005	2004	2003	2002
REVENUE	59.5	45.2	32%	100.5	79.4	59.9	52.8	43.9
GROSS PROFIT	36.6	27.8	32%	60.1	47.0	32.7	31.3	23.4
	61.5%	61.4%		59.8%	59.2%	54.5%	59.2%	53.3%
EBITDA	17.0	12.3	39%	29.2	25.1	17.8	15.7	13.5
	28.6%	27.1%		29.1%	31.6%	29.7%	29.7%	30.9%
OPERATING INCOME	15.2	11.1	37%	25.7	21.3	14.8	12.7	10.5

in USD mln.

BALANCE SHEET VEROPHARM

	1H07	2006	2005	2004	2003	2002
N-CURRENT ASSETS	41.7	40.3	35.6	35.9	34.4	31.2
CURRENT ASSETS	91.4	82.2	54.6	38.7	32.4	23.4
TOTAL ASSETS	133.1	122.5	90.2	74.6	66.8	54.5
C-NT LIABILITIES	22.5	22.0	16.3	20.4	20.1	6.5

INCOME STATEMENT

NON-CORE & MEDICAL SERVICES

	1H07	1H06	07/06	2006	2005	EMC 1H07
REVENUE	15.4	15.6	-1%	33.1	24.2	12.7
GROSS PROFIT	4.0	2.6	54%	5.5	3.7	6.9
	26.0%	16.8%		16.5%	15.1%	54.7%
EBITDA	-0.4	-0.2	n/a	-0.6	-0.1	3.5
	-2.6%	-1.2%		-1.9%	-0.5%	27.6%
OPERATING INCOME	-0.4	-0.7	n/a	-0.7	-0.2	3.2

^{*} Non-core businesses include: medical wholesale, medical engineering and toys retail

HEALTHY, FIT & STRONG

Address: 119530, Moscow, Ochakovskoye shosse, 10-2-1

Tel.: +7 (495) 792-5207

Fax: +7 (495) 792-5206

E-mail: ir@oao366.ru

www.pharmacychain366.ru www.oao366.ru